Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT07179120

/ Not yet recruitingPhase 2IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

NCT07090343

/ Not yet recruitingPhase 3IIT

Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety and efficacy of once-weekly semaglutide 2.4 mg in adult patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) who meet current clinical criteria for semaglutide treatment. A total of 826 participants will be randomized 1:1 to receive semaglutide or placebo as an add-on to standard-of-care, starting 3 months before TAVR and continuing for 24 months post-procedure. The primary endpoint is time to first occurrence of a composite of cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke or transient ischemic accident (TIA), and hospitalization for heart failure (HF). The study is event-driven and powered to detect a 20% relative risk reduction in primary outcome events. This trial aims to address the unmet need for medical therapies that improve outcomes in patients with severe AS following TAVR, with potential for direct clinical implementation.

Start Date01 Apr 2026

Sponsor / Collaborator

Leids Universitair Medisch Centrum

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

323

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

Author: Zhao, Zhenxiang ; Alvarez, Sara ; Michalak, Wojciech ; Faurby, Mads ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

01 Dec 2025·NEUROPHARMACOLOGY

GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model

Article

Author: Li, Xin-Yi ; Liu, Feng-Tao ; Xu, Zhi-Heng ; Lin, Hua-Mei ; Zhang, Meng-Wei ; Chen, Chen ; Zuo, Chuan-Tao ; Wu, Jian-Jun ; Zhao, Jue ; Wang, Jian ; Yu, Wen-Bo ; Tang, Yi-Lin ; Zhou, Wan-Yi ; Sun, Yi-Min

BACKGROUND:

Tauopathies, including Alzheimer's disease, are characterized by progressive neurodegeneration manifesting as motor and cognitive impairments. This study evaluated the therapeutic potential of semaglutide, a clinically approved glucagon-like peptide-1 receptor agonist, in the rTg4510 mouse model of tauopathy.

METHODS:

Starting at three months of age, rTg4510 mice and wild-type littermates received semaglutide (0.10 mg kg^-1, intraperitoneal) or vehicle (PBS) every other day for 16 weeks. Motor coordination, anxiety-like behavior, spatial working memory, and associative fear memory were assessed using behavioral paradigms. Tau accumulation was monitored via 18F-PM-PBB3 micro-PET/CT imaging. Immunohistochemistry and immunoblot analyses quantified tau pathology, neuronal integrity, and glial activation.

RESULTS:

Semaglutide significantly improved motor coordination in rTg4510 mice on the pole test, though not rotarod endurance. While spontaneous locomotion, anxiety-like behaviors, and Y-maze spatial working memory remained unchanged, semaglutide significantly enhanced cue-dependent freezing in fear conditioning, indicating improved associative memory. ¹⁸F-PM-PBB3 PET imaging revealed a pronounced reduction in cortical and hippocampal tracer uptake, indicative of reduced tau burden. Immunohistochemistry and Western blotting confirmed significantly decreased cortical phosphorylated tau (AT8) levels. Semaglutide preserved cortical neuronal integrity; however, no hippocampal changes were detected, likely due to minimal baseline neuron loss at this age. Astrocytic (GFAP) and microglial (Iba1) activation remained unaffected.

CONCLUSION:

Semaglutide ameliorated domain-specific motor impairments, enhanced associative fear memory, and attenuated cortical tau pathology in rTg4510 mice. These findings highlight therapeutic promise of semaglutide as a disease-modifying agent for tauopathies, justifying further dose-response, mechanistic, and translational studies.

01 Nov 2025·JACC-Heart Failure

Semaglutide and Exercise Function in Obesity-Related HFpEF

Article

Author: Núñez, Julio ; Patel, Shachi ; Verma, Subodh ; Einfeldt, Mette Nygaard ; Butler, Javed ; Davies, Melanie J ; Salsali, Afshin ; Kitzman, Dalane W ; Chinnakondepalli, Khaja M ; Kosiborod, Mikhail N ; Petrie, Mark C ; Liisberg, Karoline ; Shah, Sanjiv J ; Borlaug, Barry A

BACKGROUND:

Exercise function quantified by 6-minute walk distance (6MWD) is severely impaired in patients with heart failure with preserved ejection fraction (HFpEF).

OBJECTIVES:

This prespecified secondary analysis of pooled data from the STEP-HFpEF Program (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) examined factors associated with impaired exercise function at baseline, detailed effects of semaglutide on 6MWD, and on other key trial endpoints according to baseline 6MWD in patients with HFpEF.

METHODS:

Associates of 6MWD were assessed at baseline, and effects of semaglutide on 6MWD were evaluated at early (20 weeks) and final (52 weeks) time points, across subgroups, and according to the magnitude of weight loss achieved. Effects of semaglutide on the dual primary (changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score [KCCQ-CSS] and body weight) and secondary/exploratory endpoints were contrasted by tertiles of baseline 6MWD.

RESULTS:

The authors randomized 1,145 patients to semaglutide or placebo. Compared with patients who had obesity-related HFpEF and higher 6MWD, those with lower 6MWD were older and had lower KCCQ-CSS, higher body mass index and waist circumference, greater systemic inflammation (higher C-reactive protein), and more severe congestion (higher N-terminal pro-B-type natriuretic peptide, more diuretic use). Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m; P < 0.0001]) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m; P < 0.0001]). Increases in 6MWD with semaglutide (vs placebo) were similar across all relevant subgroups, with no significant interactions. Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro-B-type natriuretic peptide across the spectrum of baseline 6MWD (all P_interaction = NS). Each 1-unit decrease in body mass index on treatment with semaglutide was associated with a 4.1 m (95% CI: 2.4-5.7 m) increase in 6MWD (P < 0.0001).

CONCLUSIONS:

In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss. The effects were consistent across subgroups. There was strong correlation between greater magnitude of weight loss and greater improvements in 6MWD. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF], NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM], NCT04916470).

2,379

News (Medical) associated with Semaglutide (Novo Nordisk)

10 Oct 2025

·www.prnewswire.com

Parker Waichman LLP Investigates Vision Loss Cases Linked to Ozempic and Other Semaglutide Drugs Following EMA Confirmation of NAION Risk

PORT WASHINGTON, N.Y., Oct. 10, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized plaintiffs' law firm dedicated to representing victims of defective drugs and medical devices, is actively handling claims on behalf of individuals who have suffered vision loss after using Ozempic, Wegovy or other brand name semaglutide medications. The European Medicines Agency (EMA) recently confirmed a potential link between semaglutide —the active ingredient in Ozempic and Wegovy—and Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) an irreversible eye condition that causes sudden and often permanent vision loss. According to the EMA's updated Summary of Product Characteristics for Ozempic: "Data from epidemiological studies indicates an increased risk for non-arteritic anterior ischaemic optic neuropathy (NAION) during treatment with semaglutide. There is no identified time interval for when NAION may develop following treatment start. A sudden loss of vision should lead to ophthalmological examination, and treatment with semaglutide should be discontinued if NAION is confirmed." This finding adds to growing global concern regarding the safety of GLP-1 receptor agonist medications, including Ozempic and Wegovy, which were originally developed to treat Type 2 diabetes but are now widely prescribed for weight loss. Legal Action and Client Representation Parker Waichman LLP represents individuals across the United States who developed serious eye injuries—particularly vision loss or blindness related to NAION—after taking semaglutide-based drugs. The firm has already filed multiple lawsuits and continues to investigate additional claims on behalf of affected patients. "People trusted that these medications were safe for use," said Jason Goldstein, Senior Litigation Counsel, at Parker Waichman LLP. "This new EMA confirmation underscores what we have been seeing through our clients' experiences—sudden, devastating loss of vision that changes lives forever." About NAION Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) occurs when blood flow to the optic nerve is disrupted, leading to irreversible damage. Symptoms often include sudden vision loss in one or both eyes, usually without pain. There is currently no known cure, and vision typically does not return. About Parker Waichman LLP Parker Waichman LLP is one of the nation's premier personal injury and mass tort law firms, representing clients in cases involving defective drugs, medical devices, environmental exposure, and catastrophic injury. The firm has recovered billions of dollars for clients nationwide and is recognized for its advocacy on behalf of consumers against major pharmaceutical companies. Individuals who have experienced vision changes, partial blindness, or diagnosed NAION after taking Ozempic, Wegovy, or similar semaglutide drugs are encouraged to contact Parker Waichman LLP for a free case evaluation. Contact: Jason Goldstein Parker Waichman LLP 6 Harbor Park Drive, Port Washington, NY 11050 Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Patent Infringement

10 Oct 2025

·pharma.economictimes.indiatimes.com

Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout

Bagsvaerd: Danish drug giant Novo Nordisk has entered into a definitive agreement to acquire NASDAQ-listed Akero Therapeutics for a total consideration of up to $5.2 billion. Novo Nordisk will make an upfront cash payment of $4.7 billion to acquire all outstanding shares of Akero’s common stock at a price of $54 per share. Additionally, Akero shareholders are eligible for a non-transferable Contingent Value Right (CVR) of $500 million in cash at $6 per share, aggregating the total deal value to $5.2 billion. As per Novo Nordisk, the transaction has been unanimously approved by Akero’s Board of Directors and is expected to close by December-January. The weight-loss major is pushing the acquisition to onboard a late-stage liver disease drug , ‘ Efruxifermin ’ (EFX), which is currently being evaluated as a once-weekly injectable under a phase 3 program for the treatment of metabolic dysfunction-associated steatohepatitis ( MASH ). Previously, in phase 2b trials, the drug demonstrated "49 per cent and 29 per cent reduction in fibrosis--- a scare tissue which hampers recovery—without worsening of MASH. “Based on the data generated by Akero, we believe Efruxifermin could be a first- and best-in-class treatment for mid- to late-stage MASH with the potential to reverse liver damage,” said Martin Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. The deal comes days after the company secured expanded approval for its GLP-1 blockbuster Semaglutide for the same indication. “If approved, we believe it could become a cornerstone therapy, alone or together with Wegovy (Semaglutide), to tackle one of the fastest-growing metabolic diseases of our time,” said Mike Doustdar , President and CEO, Novo Nordisk. By Online Bureau ,

Phase 2Clinical ResultAcquisitionDrug ApprovalPhase 3

09 Oct 2025

·www.fiercebiotech.com

Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect

Akero Therapeutics\' drug could become a \"cornerstone therapy\" in the treatment of metabolic dysfunction-associated steatohepatitis, Novo Nordisk\'s CEO Mike Doustdar said in a statement.\n Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key name in the metabolic dysfunction-associated steatohepatitis (MASH) space in February, when the publication of data that an analyst hailed as “transformational” doubled its share price. It recently emerged that Roche responded to the data by stepping up talks with 89bio, one of Akero’s chief rivals. Roche struck its 89bio buyout last month, moving to secure the biotech\'s FGF21 analog pegozafermin.Now, Novo Nordisk has agreed to buy Akero for about $4.7 billion upfront. At $54 a share, the upfront deal value represents a 19% premium to Akero’s average stock price over the past 30 days. The biotech’s share price climbed as high as $57 in the immediate aftermath of the February data drop.Akero shareholders could bag a further $6 a share if efruxifermin (EFX) wins full U.S. regulatory approval for the treatment of compensated cirrhosis due to MASH by mid-2031. The contingent value right could swell the total value of the deal to $5.2 billion.The outlay will give Novo another angle of attack on the MASH market. EFX, a FGF21 analog, is in a phase 3 program that is scheduled to start delivering data in the first half of next year. Akero said Novo’s capabilities in cardio-metabolic disease will accelerate the evaluation of EFX in the phase 3 program. It\'s unclear when exactly Novo began its pursuit of Akero, but the biotech reportedly received buyout interest from an unnamed suitor back in May. Nevertheless, Novo has a new CEO in Mike Doustdar to put his name to the deal. In a statement, Doustdar said EFX “could become a cornerstone therapy, alone or together with Wegovy, to tackle one of the fastest-growing metabolic diseases of our time.”The FDA approved Novo\'s Wegovy in MASH in August. David Moore, Novo\'s executive vice president of U.S. operations, talked up the MASH market on an earnings call shortly before the FDA approval, touting it as a chance to “differentiate Wegovy further in terms of that strength of the label” in an indication “that entire companies have been built upon.”Novo will face competition for the opportunity. Madrigal Pharmaceuticals’ Rezdiffra is already approved in MASH, and a clutch of companies is giving chase. Roche is set to join the race through its deal to buy 89bio for up to $3.5 billion.So far, Madrigal\'s Rezdiffra has been off to a strong start since its U.S. launch last April. In the first half of this year, the drug generated $350 million.

AcquisitionDrug ApprovalPhase 3

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Nonalcoholic Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Nonalcoholic Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	gnaglpqdut(gvgvjdwegu) = cgtenukcep fsmlrrtrnu (bydbgqdevf ) View more	Positive	31 Dec 2025
NCT04916470 (STEP-HFpEF DM, Pubmed \| JACC Heart Fail)	Phase 3	-	1,145	Semaglutide	mgljystsdh(cdwbgtrunz): Difference (Semaglutide vs Placebo) = 14.6 (95.0% CI, 8.6 - 20.7), P-Value = < 0.0001 View more	Positive	01 Nov 2025
				Placebo
NCT02970942 \| NCT03552757 \| NCT03548935 (STEP 1, Pubmed \| JHEP Rep)	Phase 2	Nonalcoholic Steatohepatitis	-	Semaglutide 2.4 mg	mlitkifgpm(zlwiaqpgwq) = zuphnnownc vhzjxcgapq (wdhvaiblmu ) View more	Positive	01 Oct 2025
				Semaglutide 1.0 mg	mlitkifgpm(zlwiaqpgwq) = lkimpdbhjo vhzjxcgapq (wdhvaiblmu ) View more
NCT03914326 (SOUL, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Myocardial Infarction \| Heart Diseases ... View more	9,651	Semaglutide (Oral Semaglutide)	nrcduecmwl = fzhaeffejz aejnvbqllo (fzgypahucl, dtcgsavzob - kmjegngrhf) View more	-	22 Sep 2025
				Placebo (semaglutide) (Placebo)	nrcduecmwl = osjtavbvbz aejnvbqllo (fzgypahucl, vhcvfravtj - sabmzlzbeu) View more
NCT05564117 (OASIS 4, Pubmed \| N Engl J Med)	Phase 3	-	307	Oral Semaglutide 25 mg	unbuzdgmro(bjjuynsqkp) = oclgaktbzt qiuraqljmi (xvqznmexhw )	Positive	18 Sep 2025
				Placebo	unbuzdgmro(bjjuynsqkp) = otlhyvybvm qiuraqljmi (xvqznmexhw )
NCT04126603 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	10	Placebos (Group A Placebo)	cakpqzyiku(cescqdlfyr) = qvwhyckshg ezhhbmzbqj (mhxgzefrfu, 0.06) View more	-	09 Sep 2025
				Semaglutide (Group B Active)	cakpqzyiku(cescqdlfyr) = zcgoimnvcf ezhhbmzbqj (mhxgzefrfu, 0.16) View more
NCT05193578 (Pubmed \| JAMA Psychiatry)	Phase 3	Schizophrenia	154	Semaglutide	qfbzresqkn(guqspdugua) = cebnlksyzv xsuttccbqq (jasavijssg, 1.52 - 5.98) View more	Positive	03 Sep 2025
STEER (PRNewswire \| NEWS) Manual	Not Applicable	Obesity	-	Wegovy 2.4 mg	jrkofdrhqk(defptiphzf) = Wegovy showed a significant 29% risk reduction compared with tirzepatide. myukwzlrpw (tmjgntncma ) View more	Positive	01 Sep 2025
				Tirzepatide
NCT06914141 \| NCT06914154 \| NCT06914102 (JAMA) Manual	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	dpvneegkcg(wurlmsrxgw): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	31 Aug 2025
				sitagliptin
NCT05537233 (ADJUST-T1D, CTgov)	Phase 2	Diabetes Mellitus, Type 1 \| Obesity	115	Semaglutide (Semaglutide)	nyjexfealz = rhxwdafcwe vdydxbamrc (mtkixxgxdn, husugzkjgr - wwbdqpzlxq) View more	-	12 Aug 2025
				Placebo (Control)	nyjexfealz = ixrlffkscs vdydxbamrc (mtkixxgxdn, bamtewfvir - nweustwuld) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis